HK Stock Market Move | LONGBIO-B(01779) rose more than 7% recently. The clinical trial application for peanut allergy adaptation syndrome LP-003 has been approved by the US FDA.

LONGBIO-B(01779) rose more than 7%, rising by 7.77% to HK$89.45 as of the time of writing, with a turnover of HK$3.1726 million. On the news front, recently, LONGBIO-B(01779) announced that the clinical trial application for LP-003 for peanut allergy has been approved by the U.S. Food and Drug Administration (FDA). LP-003 is a novel anti-IgE antibody with a new sequence design. As anti-IgE antibodies can block the cascade process of allergic reactions, they currently play a key role in the treatment of various allergic diseases. Anti-IgE therapy has been included in the diagnosis and treatment guidelines for seasonal allergic rhinitis and CSU in China. The company has obtained IND approval for LP-003 for multiple indications in China and/or initiated related clinical trials, including seasonal allergic rhinitis, CSU, allergic asthma, CRSwNP, and food allergies.